Deal Watch: Teva and Regeneron Announce Fasinumab Collaboration

On September 20, Teva Pharmaceutical Industries Ltd. and Regeneron Pharmaceuticals, Inc. announced an agreement to develop and commercialize fasinumab, an investigational NGF antibody currently under development by Regeneron as a treatment for osteoarthritis and chronic low back pain.   The press release states Teva and Regeneron will collaborate globally, excluding Japan, Korea, and 9 other Asian countries that are part of a previous fasinumab collaboration between Regeneron and Mitsubishi Tanabe Pharma.

According to the announcement, under the terms of the agreement, Teva will make an initial upfront payment of $250 million to Regeneron, and the companies will share equally in the ongoing R&D costs (estimated at approximately $1 billion) and the value of the commercialized product.